The researchers confirmed that low-dose Apatinib enhances the infiltration of CD8+ T cells while reducing the recruitment of tumor-associated macrophages within the tumor microenvironment, thereby optimizing its conditions (48). This evidence concerns the gene CD8A and neoplasm.